Sara Imhof, Ph.D., vice president of the focused initiatives team at the North Carolina Biotechnology Center, has been honored by a regional business publication for her inspiring work to lead North ...

Redbud has introduced its microfluidics sample prep platform, called Redbud NA1, for use in research and surveillance for ...

“The KickStart Grant Awards help de-risk these technologies by establishing a collaboration agreement between the startup ...

Join Innovate Carolina on Tuesday, March 18 for a deep dive into the future of an exciting new crop plant, Stevia, powered by cutting-edge technology and innovative approaches to sustainable ...

Flourish Research, a multi-site clinical trials company based in Apex, has acquired a California clinical research facility.

The UNC School of Law in conjunction with Eshelman Innovation at the UNC Eshelman School of Pharmacy, will host the Institute for Innovation Speaker Series on March 17. The esteemed panel will discuss ...

Two pharmaceutical companies with operations in North Carolina are joining forces for a greater impact on women’s health. Cosette Pharmaceuticals, based in Bridgewater, N.J., with a pharmaceutical ...

What started as a regional effort to support local biotechnology startups in southeast North Carolina is now championing entrepreneurs in all five of the North Carolina Biotechnology Center’s regions ...

That message is abundantly clear in the newly published analysis, "Evidence & Opportunity 2022: Impact of Life Sciences in NC," which documents why North Carolina continues to garner global admiration ...

AveXis, an Illinois-based clinical-stage company developing gene therapies for neurological genetic diseases, is investing $55 million in a new Durham manufacturing facility that will create 200 jobs.

Doron Therapeutics, a clinical-stage biotechnology company based in Chapel Hill, has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration ...

Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs, doubling its workforce there. The ...